Ruthigen Inc. (RTGN) 4.20 $RTGN
Oculus Innovative Sciences Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Thu Feb 12, 3:09PM CST
-- Total revenue of $3.2 million for the third quarter
RTGN: 4.20 (+0.08), OCLS: 0.80 (-0.01)
Oculus Innovative Sciences to divest Ruthigen shares for USD5.5m in event of Ruthigen merger
M2 - Mon Jan 12, 6:53AM CST
Pharmaceutical company Oculus Innovative Sciences (NasdaqCM:OCLS) reported on Monday the launch of a securities purchase agreement with two current Ruthigen investors.
RTGN: 4.20 (+0.08), OCLS: 0.80 (-0.01)
Oculus Innovative Sciences Enters Into Agreement to Sell Ruthigen, Inc. Shares for $5.5 Million in Event of Ruthigen Merger
GlobeNewswire - Mon Jan 12, 5:35AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that the company has entered into a securities purchase agreement with two current Ruthigen investors, under which these two buyers agree to purchase all of Oculus' two million Ruthigen (Nasdaq:RTGN) shares at $2.75 per share, or an aggregate of $5.5 million. The agreement expires in 60 days and is subject to Ruthigen entering into a definitive agreement for a merger.
RTGN: 4.20 (+0.08), OCLS: 0.80 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 12:03PM CST
IHT: 2.90 (-0.04), NES: 3.52 (+0.13), VJET: 10.40 (+0.45), AHC: 9.13 (+0.08), OSGB: 5.14 (+0.04), SYNC: 2.18 (+0.05), SYRX: 1.50 (-0.06), JOB: 0.79 (+0.01), LIVE: 3.23 (-0.22), PME: 2.42 (-0.07), ATOS: 1.67 (+0.11), BWEN: 5.48 (+0.15), KEG: 2.14 (+0.08), AKER: 3.50 (+0.20), XONE: 16.93 (-0.16), MCHX: 4.34 (-0.01), SPP: 1.36 (unch), RTGN: 4.20 (+0.08), ATEA: 1.76 (+0.01)
Strong Portfolio, Dividends Make Merck An Attractive Opportunity
Kanak Kanti De - at Seeking Alpha - Mon Dec 08, 2:40PM CST
TTPH: 35.18 (-0.73), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07), RTGN: 4.20 (+0.08)
Ruthigen EPS of -$0.35
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:46PM CST
RTGN: 4.20 (+0.08)
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Thu Nov 13, 3:08PM CST
-- Total revenue of $3.3 million for the second quarter
OCLS: 0.80 (-0.01), RTGN: 4.20 (+0.08)
Ruthigen Reports Fiscal Second Quarter 2015 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fiscal second quarter 2015 ended September 30, 2014.
RTGN: 4.20 (+0.08)
Ruthigen To Hold Fiscal Second Quarter 2015 Financial Results Conference Call On Thursday, November 13, 2014
PR Newswire - Thu Nov 06, 6:00AM CST
Ruthigen, Inc., (NASDAQ: RTGN) today announced that the financial results for its fiscal second quarter 2015, ended September 30, 2014, will be released after the U.S. markets close on November 13, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PDT (4:30 p.m. EDT) on November 13, 2014, to discuss fiscal second quarter 2015 results.
RTGN: 4.20 (+0.08)
Ruthigen Announces First Patient Enrollment in the Phase 1/2 Human Clinical Trial of RUT58-60, a Broad-Spectrum Anti-Infective Drug Candidate Designed for Prophylactic Use During Invasive Surgery
PR Newswire - Tue Nov 04, 6:00AM CST
Ruthigen, Inc. (NASDAQ: RTGN), announced today enrollment of the first patient in a Randomized, Double-Blind Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.
RTGN: 4.20 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Tue Oct 21, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
EGLT: 10.60 (+0.58), XPLR: 7.00 (+0.26), ILMN: 198.54 (+1.81), SYNL: 15.78 (+0.51), QVCB: 28.95 (+0.05), CZR: 10.78 (+0.18), QVCA: 29.47 (+0.42), ORPN: 7.17 (+0.04), SHLD: 35.70 (+2.32), RTGN: 4.20 (+0.08)
Ruthigen Initiates Phase 1/2 Clinical Trial of RUT58-60
PR Newswire - Wed Oct 08, 6:00AM CDT
Ruthigen Inc. (NASDAQ: RTGN), a biopharmaceutical company focused on pioneering new therapies to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures, announces the initiation of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.
RTGN: 4.20 (+0.08)
IPO Value Surges To The Highest Level In More Than a Decade
ACCESSWIRE - Fri Sep 19, 11:52AM CDT
Deerfield Beach, FL / September 19, 2014 / As the U.S. economy continues to recover, deal making activity has surged. Indeed, both M&As and initial public offerings (IPO) have seen a surge this year. In fact data from Dealogic shows that companies raised $46.4 billion in the first eight months of 2014, the highest of any year since 2000. The value of IPOs will get a huge boost as Chinese e-commerce company Alibaba Group Holding Ltd. (NYSE: BABA) completed its IPO on Thursday.
RICE: 19.13 (-0.22), FB: 75.74 (-0.49), FOMX: 9.01 (-0.03), RSPP: 28.48 (+1.29), RTGN: 4.20 (+0.08), BABA: 89.05 (+1.95)
Ruthigen to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City
PR Newswire - Thu Sep 04, 6:00AM CDT
Ruthigen, Inc., (NASDAQ: RTGN) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at 2:30 p.m. ET. The conference will be held at the New York Palace Hotel in New York City.
RTGN: 4.20 (+0.08)
Ruthigen Receives Recommendation from Data Monitoring Committee to Initiate Phase 1/2 Human Clinical Trial of RUT58-60
PR Newswire - Tue Aug 26, 6:00AM CDT
Ruthigen Inc. (NASDAQ: RTGN), a biopharmaceutical company focused on improving patient outcomes and reducing healthcare costs in invasive procedures, has announced that its lead drug candidate, RUT58-60, has received a recommendation from the Data Monitoring Committee (DMC) to begin enrolling patients in the Company's planned Phase 1/2 clinical trial.
RTGN: 4.20 (+0.08)
Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.
ACHN: 10.89 (-0.20), AVEO: 0.84 (-0.06), AEGR: 25.15 (+0.88), RTGN: 4.20 (+0.08)
Ruthigen Reports Fiscal First Quarter 2015 Financial Results
PR Newswire - Thu Aug 14, 3:17PM CDT
Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fiscal first quarter 2015 ended June 30, 2014.
RTGN: 4.20 (+0.08)
Oculus Innovative Sciences Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Thu Feb 12, 3:09PM CST
-- Total revenue of $3.2 million for the third quarter
RTGN: 4.20 (+0.08), OCLS: 0.80 (-0.01)
Oculus Innovative Sciences to divest Ruthigen shares for USD5.5m in event of Ruthigen merger
M2 - Mon Jan 12, 6:53AM CST
Pharmaceutical company Oculus Innovative Sciences (NasdaqCM:OCLS) reported on Monday the launch of a securities purchase agreement with two current Ruthigen investors.
RTGN: 4.20 (+0.08), OCLS: 0.80 (-0.01)
Oculus Innovative Sciences Enters Into Agreement to Sell Ruthigen, Inc. Shares for $5.5 Million in Event of Ruthigen Merger
GlobeNewswire - Mon Jan 12, 5:35AM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced that the company has entered into a securities purchase agreement with two current Ruthigen investors, under which these two buyers agree to purchase all of Oculus' two million Ruthigen (Nasdaq:RTGN) shares at $2.75 per share, or an aggregate of $5.5 million. The agreement expires in 60 days and is subject to Ruthigen entering into a definitive agreement for a merger.
RTGN: 4.20 (+0.08), OCLS: 0.80 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 12:03PM CST
IHT: 2.90 (-0.04), NES: 3.52 (+0.13), VJET: 10.40 (+0.45), AHC: 9.13 (+0.08), OSGB: 5.14 (+0.04), SYNC: 2.18 (+0.05), SYRX: 1.50 (-0.06), JOB: 0.79 (+0.01), LIVE: 3.23 (-0.22), PME: 2.42 (-0.07), ATOS: 1.67 (+0.11), BWEN: 5.48 (+0.15), KEG: 2.14 (+0.08), AKER: 3.50 (+0.20), XONE: 16.93 (-0.16), MCHX: 4.34 (-0.01), SPP: 1.36 (unch), RTGN: 4.20 (+0.08), ATEA: 1.76 (+0.01)
Strong Portfolio, Dividends Make Merck An Attractive Opportunity
Kanak Kanti De - at Seeking Alpha - Mon Dec 08, 2:40PM CST
TTPH: 35.18 (-0.73), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07), RTGN: 4.20 (+0.08)
Ruthigen EPS of -$0.35
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:46PM CST
RTGN: 4.20 (+0.08)
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015
GlobeNewswire - Thu Nov 13, 3:08PM CST
-- Total revenue of $3.3 million for the second quarter
OCLS: 0.80 (-0.01), RTGN: 4.20 (+0.08)
Ruthigen Reports Fiscal Second Quarter 2015 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fiscal second quarter 2015 ended September 30, 2014.
RTGN: 4.20 (+0.08)
Ruthigen To Hold Fiscal Second Quarter 2015 Financial Results Conference Call On Thursday, November 13, 2014
PR Newswire - Thu Nov 06, 6:00AM CST
Ruthigen, Inc., (NASDAQ: RTGN) today announced that the financial results for its fiscal second quarter 2015, ended September 30, 2014, will be released after the U.S. markets close on November 13, 2014. The earnings release will be followed by a conference call at 1:30 p.m. PDT (4:30 p.m. EDT) on November 13, 2014, to discuss fiscal second quarter 2015 results.
RTGN: 4.20 (+0.08)
Ruthigen Announces First Patient Enrollment in the Phase 1/2 Human Clinical Trial of RUT58-60, a Broad-Spectrum Anti-Infective Drug Candidate Designed for Prophylactic Use During Invasive Surgery
PR Newswire - Tue Nov 04, 6:00AM CST
Ruthigen, Inc. (NASDAQ: RTGN), announced today enrollment of the first patient in a Randomized, Double-Blind Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.
RTGN: 4.20 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Tue Oct 21, 12:44PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
EGLT: 10.60 (+0.58), XPLR: 7.00 (+0.26), ILMN: 198.54 (+1.81), SYNL: 15.78 (+0.51), QVCB: 28.95 (+0.05), CZR: 10.78 (+0.18), QVCA: 29.47 (+0.42), ORPN: 7.17 (+0.04), SHLD: 35.70 (+2.32), RTGN: 4.20 (+0.08)
Ruthigen Initiates Phase 1/2 Clinical Trial of RUT58-60
PR Newswire - Wed Oct 08, 6:00AM CDT
Ruthigen Inc. (NASDAQ: RTGN), a biopharmaceutical company focused on pioneering new therapies to improve patient outcomes and reduce healthcare costs associated with infections related to post-operative invasive procedures, announces the initiation of a Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.
RTGN: 4.20 (+0.08)
IPO Value Surges To The Highest Level In More Than a Decade
ACCESSWIRE - Fri Sep 19, 11:52AM CDT
Deerfield Beach, FL / September 19, 2014 / As the U.S. economy continues to recover, deal making activity has surged. Indeed, both M&As and initial public offerings (IPO) have seen a surge this year. In fact data from Dealogic shows that companies raised $46.4 billion in the first eight months of 2014, the highest of any year since 2000. The value of IPOs will get a huge boost as Chinese e-commerce company Alibaba Group Holding Ltd. (NYSE: BABA) completed its IPO on Thursday.
RICE: 19.13 (-0.22), FB: 75.74 (-0.49), FOMX: 9.01 (-0.03), RSPP: 28.48 (+1.29), RTGN: 4.20 (+0.08), BABA: 89.05 (+1.95)
Ruthigen to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City
PR Newswire - Thu Sep 04, 6:00AM CDT
Ruthigen, Inc., (NASDAQ: RTGN) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at 2:30 p.m. ET. The conference will be held at the New York Palace Hotel in New York City.
RTGN: 4.20 (+0.08)
Ruthigen Receives Recommendation from Data Monitoring Committee to Initiate Phase 1/2 Human Clinical Trial of RUT58-60
PR Newswire - Tue Aug 26, 6:00AM CDT
Ruthigen Inc. (NASDAQ: RTGN), a biopharmaceutical company focused on improving patient outcomes and reducing healthcare costs in invasive procedures, has announced that its lead drug candidate, RUT58-60, has received a recommendation from the Data Monitoring Committee (DMC) to begin enrolling patients in the Company's planned Phase 1/2 clinical trial.
RTGN: 4.20 (+0.08)
Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.
ACHN: 10.89 (-0.20), AVEO: 0.84 (-0.06), AEGR: 25.15 (+0.88), RTGN: 4.20 (+0.08)
Ruthigen Reports Fiscal First Quarter 2015 Financial Results
PR Newswire - Thu Aug 14, 3:17PM CDT
Ruthigen, Inc. (NASDAQ: RTGN) today reported financial results for its fiscal first quarter 2015 ended June 30, 2014.
RTGN: 4.20 (+0.08)
